Navigation Links
Inhaled Insulin: A New Modality for Management of Diabetes

It is widely known that diabetes, one of the world’s leading debilitating diseases, has reached overwhelming proportions // . It affects an estimated 194 million adults worldwide. Therefore, there is a huge demand for innovative and effective therapeutic options that are beneficial to the patients.

There are two types of diabetes:

Type-1: Also known as Juvenile Diabetes, it accounts for approximately 5% of all the cases. This type is the direct result of the body’s inability to produce sufficient Insulin required for the breakdown of sugar.

Type-2: This results from the body not availing the Insulin that is present and is often associated with ageing, obesity and lack of physical activity.

On Saturday (June 9, 2006) the pharmaceutical company, Pfizer, announced the arrival of its 'Inhaled Insulin' Exubera, which will be available from July all over the United States. It is the first non-injectable Insulin to be marketed and is a revolutionary change in the management of Diabetes. The drug has been approved by the FDA. This announcement was made by Pfizer, along with its partner Nektar Therapeutics, at the annual scientific meeting of the American Diabetics Association.

It is claimed that the drug is far more user- friendly than the injectable version. A price has not yet been assigned to the drug.

Having been approved by the EU, diabetics in Europe also will have access to the drug.

In the US, the drug has been approved to treat both Type 1 and Type 2 Diabetes. Taken at mealtime, the patient inhales the Insulin through the mouth and the drug then is rapidly delivered into the lungs. The lungs are considered a safe place for its absorption due to its large and permeable surface area. From here it pass into the blood stream.

Pfizer recommends that Type 1 patients use Exubera along with the injections, while the Type 2 patients may use it alone or in combination with the in
'"/>




Page: 1 2

Related medicine news :

1. Inhaled Steroids Safe & Effective for Children with Asthma
2. Inhaled Corticosteroids Found To Have No Significant Effect On COPD
3. The Effectiveness Of Inhaled Corticosteroids Studied
4. The Effectiveness Of Inhaled Corticosteroids Studied
5. Inhaled nitric oxide therapy does not reduce death risk of infants
6. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
7. HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy
8. Inhaled Insulin To Be Made Available in India
9. Inhaled Insulin Could Rock The Drug Market Soon
10. High Cost Forces NHS To Reject Inhaled Insulin
11. Inhaled Cyclosporine Results In Rejection Free Survival among Lung Transplant Patients
Post Your Comments:
Breaking Medicine News(10 mins):Health News:You Never Get a Second Chance to Make a First Impression: High-Definition for the Web 2Health News:Moravia Worldwide to Present Live Webinar on Creation and Use of Terminology in Localization 2Health News:Moravia Worldwide to Present Live Webinar on Creation and Use of Terminology in Localization 3Health News:Lung Cancer Alliance Praises Growing National Coalition 2Health News:Lung Cancer Alliance Praises Growing National Coalition 3Health News:Book Offers Help for Parents Struggling with Difficult Teens During the Upcoming Holidays 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 4
Breaking Medicine Technology:RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 2RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 3AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Marc Russo Named Vice President of Senior Markets at Blue Shield of California 57132 1Marc Russo Named Vice President of Senior Markets at Blue Shield of California 57132 2MUSC Researchers Concerned About Online Drug Availability 57128 1MUSC Researchers Concerned About Online Drug Availability 57128 2HealthSouth Declares Dividend on 6 5 25 Series A Convertible Perpetual Preferred Stock 57123 1